Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

0.9700
-0.0900-8.49%
Volume:94.60K
Turnover:94.86K
Market Cap:25.85M
PE:-3.40
High:1.08
Open:1.08
Low:0.9500
Close:1.06
52wk High:3.40
52wk Low:0.7069
Shares:26.65M
Float Shares:21.83M
Volume Ratio:0.71
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.51
PE(LYR):-2.47

Loading ...

Analyst Reiterates Buy on Definium Therapeutics, Maintains $75 Price Target Following De-Risking of DT120 ODT in MDD and GAD

TIPRANKS
·
Yesterday

Mizuho survey shows no consensus into Alkermes ADHD data

TIPRANKS
·
Sep 05

Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In

Simply Wall St.
·
Sep 02

Blinklab Showcases AI Smartphone Platform for Autism and ADHD Diagnosis

TIPRANKS
·
Sep 01

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

GlobeNewswire
·
Aug 31

Lilly’s Brenipatide Steps Into Phase 3: A New Long-Term Play in Depression Care

TIPRANKS
·
Aug 28

ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction

TIPRANKS
·
Aug 27

ABVC Biopharma Completes BioKey Cayman Spinoff, Distributes 15% Stake to Shareholders

Reuters
·
Aug 27

Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Dow Jones
·
Aug 13

ABVC Biopharma FY26 Q2 Net Loss Narrows 65% to $810,481

Reuters
·
Aug 13

ABVC BioPharma Delays BioKey (Cayman) Share Distribution to Aug. 21 from Aug. 3 in 8-K Amendment

Reuters
·
Aug 13

ABVC Biopharma - Biokey (Cayman) Share Distribution Rescheduled for August 21, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 13

ABVC Biopharma - Postpones Biokey (Cayman) Share Distribution - SEC Filing

THOMSON REUTERS
·
Aug 13

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

GlobeNewswire
·
Aug 11

Collegium Q2 2026 earnings: ADHD growth offsets pain portfolio pressure

TradingKey
·
Aug 07

Yukiguni Maitake Sees FY Net Y2.54b

Dow Jones
·
Aug 06

BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%

MT Newswires Live
·
Aug 05

NASDAQ Trade Halt Halt News Pending at 04:43 Pm

Reuters
·
Aug 04

Press Release: Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Dow Jones
·
Aug 03

BlinkLab requests ASX trading halt ahead of material ADHD study results

TIPRANKS
·
Aug 03